Shares of Core Laboratories NV (NYSE:CLB) saw unusually-high trading volume on Friday . Approximately 482,205 shares traded hands during mid-day trading, an increase of 3% from the previous session’s volume of 468,934 shares.The stock last traded at $117.17 and had previously closed at $118.24.

CLB has been the topic of a number of research reports. ABN Amro lowered shares of Core Laboratories NV from a “buy” rating to a “sell” rating in a research report on Friday, April 22nd. Morgan Stanley boosted their price objective on shares of Core Laboratories NV from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 19th. Stephens initiated coverage on shares of Core Laboratories NV in a research report on Tuesday, April 5th. They issued an “equal weight” rating and a $89.00 price objective on the stock. Citigroup Inc. boosted their price objective on shares of Core Laboratories NV from $115.00 to $123.00 and gave the stock a “neutral” rating in a research report on Monday, May 16th. Finally, Howard Weil boosted their price objective on shares of Core Laboratories NV to $112.00 in a research report on Monday, March 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $121.00.

The company’s 50-day moving average is $123.20 and its 200-day moving average is $113.57. The firm has a market cap of $5.16 billion and a price-to-earnings ratio of 62.98.

Core Laboratories NV (NYSE:CLB) last posted its quarterly earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.35. The business earned $148.10 million during the quarter, compared to analyst estimates of $146.37 million. During the same period in the previous year, the business posted $0.81 EPS. The business’s revenue for the quarter was down 27.4% compared to the same quarter last year. Analysts anticipate that Core Laboratories NV will post $1.61 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Monday, July 18th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 1.85%. The ex-dividend date of this dividend is Thursday, July 14th.

Other institutional investors recently modified their holdings of the company. Poplar Forest Capital LLC boosted its position in shares of Core Laboratories NV by 2.7% in the fourth quarter. Poplar Forest Capital LLC now owns 9,650 shares of the company’s stock valued at $1,049,000 after buying an additional 250 shares during the period. WCM Investment Management CA boosted its position in shares of Core Laboratories NV by 44.5% in the fourth quarter. WCM Investment Management CA now owns 3,188,453 shares of the company’s stock valued at $346,713,000 after buying an additional 981,243 shares during the period. Aberdeen Asset Management PLC UK bought a new position in shares of Core Laboratories NV during the fourth quarter valued at $5,554,000. Howland Capital Management LLC boosted its position in shares of Core Laboratories NV by 4.7% in the fourth quarter. Howland Capital Management LLC now owns 102,070 shares of the company’s stock valued at $11,099,000 after buying an additional 4,562 shares during the period. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Core Laboratories NV during the fourth quarter valued at $1,043,000.

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.